Senseonics, the company behind the Eversense 365 implantable continuous glucose monitor (CGM), is working on a next-generation CGM platform that could significantly change how implantable sensors are used. This project, called Eversense Gemini focuses on reducing on-body hardware.

Eversense Gemini is a self-powered implantable CGM designed to last a full year. Unlike the current system, it includes an internal battery and can store up to eight hours of glucose data directly on the sensor. Users would be able to retrieve that data by scanning their smartphone. Gemini is being developed with three different usage modes. A continuous mode delivers real-time glucose readings every five minutes when the transmitter is worn. A scan-only mode allows users to go without a transmitter and check stored data when needed. And a flex mode would let users switch between those two options based on their preferences. Senseonics says feasibility work is still ongoing as they evaluate how these modes could fit different lifestyles and use cases.

Beyond Gemini, a future system called “Freedom” could takes things further by eliminating the external transmitter altogether. It would integrate Bluetooth Low Energy directly into the sensor, allowing data to be sent to a smartphone or insulin pump every five minutes. This technology could enable fully automated insulin delivery—no scanning and no on-body hardware. Senseonics is currently completing feasibility testing, preparing an IDE submission, and planning clinical trials. We spoke with Senseonics about both next-gen CGM projects on our podcast.

Meanwhile, Senseonics is currently distributing the Eversense 365, a one-year implantable sensor that provides continuous monitoring readings. The system recently gained compatibility through an integration with the twiist insulin pump (currently in a limited release), further expanding CGM options for pump users.

Beyond these projects, several companies are working on next-generation CGMs, including Glucotrack’s CBGM sensor that measures glucose levels directly from the bloodstream and could last up to three years. Together, these efforts point to a future where glucose monitoring becomes more seamless and less visible.

What do you think about the future of fully implantable glucose monitoring? Share your thoughts in the comments.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.